SCHEMBL8096416

SCHEMBL8096416

COc1cccc(-c2cn3c(=O)[nH]c4c(c3n2)CCCC4)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 6/20 0.67
GABRA2 P47869 6/20 0.67
WDR5 P61964 1/20 0.50
KDM4E B2RXH2 3/20 0.47
RAB9A P51151 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 2/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPT P10636 2/20 0.47
MEN1 O00255 1/20 0.47
USP2 O75604 1/20 0.47
TP53 P04637 1/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
KMT2A Q03164 1/20 0.47
HSD17B10 Q99714 1/20 0.47
GAA P10253 2/20 0.46
ADORA2A P29274 2/20 0.45
ADORA1 P30542 2/20 0.45
GABRA5 P31644 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8097270 0.87 GABRA1 (0.63) GABRA1GABRA2WDR5RAB9ASMN1; SMN2
SCHEMBL8101242 0.86 GABRA1 (0.50) GABRA1GABRA2GABRA5GABRA3
SCHEMBL8103362 0.84 GABRA2 (0.65) GABRA1GABRA2GABRA5GABRA3
SCHEMBL8103080 0.84 MAPK13 (0.57) GABRA1GABRA2KDM4ERAB9ASMN1; SMN2
SCHEMBL8101160 0.83 GABRA1 (0.55) GABRA1GABRA2GABRA5GABRA3
SCHEMBL8094714 0.83 GABRA2 (0.64) GABRA1GABRA2GABRA5GABRA3
SCHEMBL8103380 0.81 GABRA3 (0.56) GABRA1GABRA2GABRA5GABRA3
SCHEMBL9001258 0.80 GABRA1 (1.00) GABRA1GABRA2GABRA5GABRA3
SCHEMBL8088161 0.78 GABRA1 (0.61) GABRA1GABRA2KDM4ERAB9ASMN1; SMN2
SCHEMBL8885602 0.78 GABRA3 (0.51) GABRA1GABRA2GABRA5GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5426186-A Diagnosis, treatment of anxiety, sleep and seizure disorders, benzodiazepine overdose; enhancement of alertness NEUROGEN CORPORATION (US) 1995-06-20 US claimed
EP-0547168-A1 CERTAIN CYCLOALKYL IMIDAZOPYRIMIDINES, A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 1993-06-23 EP claimed
WO-1992004351-A1 CERTAIN CYCLOALKYL IMIDAZOPYRIMIDINES, A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 1992-03-19 WO claimed
US-6013799-A HIGHLY SELECTIVE AGONISTS, ANTAGONISTS OR INVERSE AGONISTS FOR G-AMINOBUTYRIC ACID (GABA) BRAIN RECEPTORS; USEFUL IN DIAGNOSIS/TREATMENT OF ANXIETY, SLEEP, AND SEIZURE DISORDERS, DRUG OVERDOSE, AND ALERTNESS ENHANCEMENT ALERTNESS NEUROGEN CORPORATION (US) 2000-01-11 US disclosed
US-5696260-A AGONSIT, ANTAGONIST, PRODRUG; USEFUL IN DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP, SEIZURE DISORDER, OVERDOSE WITH BENZODIAZEPINE TYPE DRUGS AND ENHANCEMENT OF ALERTNESS NEUROGEN CORPORATION (US) 1997-12-09 US disclosed
US-5426186-A Diagnosis, treatment of anxiety, sleep and seizure disorders, benzodiazepine overdose; enhancement of alertness NEUROGEN CORPORATION (US) 1995-06-20 US disclosed